Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous microfragmented adipose tissue (MFAT) is a biological therapeutic derived from the patient's own adipose tissue through mechanical processing that preserves the vascular-stromal niche. Unlike enzymatic digestion, the microfragmentation process maintains the structural integrity of the tissue, including mesenchymal stem cells (MSCs), pericytes, and the extracellular matrix. In the context of temporomandibular joint (TMJ) osteoarthritis, MFAT is harvested (specifically from the buccal fat pad in studies by Cairo University) and injected intra-articularly. It functions by providing a bioactive scaffold and a sustained release of trophic and anti-inflammatory factors that promote tissue repair, modulate the immune environment, and reduce joint pain and inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous microfragmented adipose tissue.